BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 26460958)

  • 1. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
    Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
    Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.
    Orecchia P; Conte R; Balza E; Petretto A; Mauri P; Mingari MC; Carnemolla B
    Eur J Cancer; 2013 May; 49(8):2022-33. PubMed ID: 23352437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model.
    Orecchia P; Balza E; Pietra G; Conte R; Bizzarri N; Ferrero S; Mingari MC; Carnemolla B
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31443604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversing effect of Lupeol on vasculogenic mimicry in murine melanoma progression.
    Bhattacharyya S; Mitra D; Ray S; Biswas N; Banerjee S; Majumder B; Mustafi SM; Murmu N
    Microvasc Res; 2019 Jan; 121():52-62. PubMed ID: 30381268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma.
    Schnegg CI; Yang MH; Ghosh SK; Hsu MY
    Cancer Res; 2015 Apr; 75(8):1682-90. PubMed ID: 25769726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
    Schwager K; Hemmerle T; Aebischer D; Neri D
    J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
    Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C
    Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry.
    Liu R; Cao Z; Tu J; Pan Y; Shang B; Zhang G; Bao M; Zhang S; Yang P; Zhou Q
    Pigment Cell Melanoma Res; 2012 Sep; 25(5):630-8. PubMed ID: 22781316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
    de Aguiar RB; Parise CB; Souza CR; Braggion C; Quintilio W; Moro AM; Navarro Marques FL; Buchpiguel CA; Chammas R; de Moraes JZ
    Cancer Lett; 2016 Feb; 371(2):151-60. PubMed ID: 26655277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
    Pretto F; Elia G; Castioni N; Neri D
    Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
    Lai CY; Schwartz BE; Hsu MY
    Cancer Res; 2012 Oct; 72(19):5111-8. PubMed ID: 22865455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
    Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
    Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes.
    Zhang C; Chen W; Zhang X; Huang B; Chen A; He Y; Wang J; Li X
    Sci Rep; 2016 Mar; 6():23056. PubMed ID: 26976322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
    Zegers CM; Rekers NH; Quaden DH; Lieuwes NG; Yaromina A; Germeraad WT; Wieten L; Biessen EA; Boon L; Neri D; Troost EG; Dubois LJ; Lambin P
    Clin Cancer Res; 2015 Mar; 21(5):1151-60. PubMed ID: 25552483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.
    Frank NY; Schatton T; Kim S; Zhan Q; Wilson BJ; Ma J; Saab KR; Osherov V; Widlund HR; Gasser M; Waaga-Gasser AM; Kupper TS; Murphy GF; Frank MH
    Cancer Res; 2011 Feb; 71(4):1474-85. PubMed ID: 21212411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGFR1 and PKCα signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner.
    Vartanian A; Stepanova E; Grigorieva I; Solomko E; Baryshnikov A; Lichinitser M
    Melanoma Res; 2011 Apr; 21(2):91-8. PubMed ID: 21389833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
    Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
    Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype.
    Yao L; Zhang D; Zhao X; Sun B; Liu Y; Gu Q; Zhang Y; Zhao X; Che N; Zheng Y; Liu F; Wang Y; Meng J
    J Cell Mol Med; 2016 Sep; 20(9):1673-85. PubMed ID: 27240974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.